Literature DB >> 16816262

From optimism to disillusion about commitment to transparency in the medico-industrial complex.

Iain Chalmers1.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16816262      PMCID： PMC1484602          DOI： 10.1177/014107680609900715

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  16 in total

1.  The uncertainty principle and industry-sponsored research.

Authors:  B Djulbegovic; M Lacevic; A Cantor; K K Fields; C L Bennett; J R Adams; N M Kuderer; G H Lyman
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

Review 2.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Authors:  Joel Lexchin; Lisa A Bero; Benjamin Djulbegovic; Otavio Clark
Journal:  BMJ       Date:  2003-05-31

Review 3.  Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.

Authors:  Hans Melander; Jane Ahlqvist-Rastad; Gertie Meijer; Björn Beermann
Journal:  BMJ       Date:  2003-05-31

4.  Good publication practice for pharmaceutical companies.

Authors:  Elizabeth Wager; Elizabeth A Field; Leni Grossman
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

5.  In the dark: drug companies should be forced to publish all the results of clinical trials.

Authors:  Iain Chalmers
Journal:  New Sci       Date:  2004 Mar 6-12       Impact factor: 0.319

6.  Open access to industry's clinically relevant data.

Authors:  Andrew Herxheimer
Journal:  BMJ       Date:  2004-07-10

7.  Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials.

Authors:  Mohit Bhandari; Jason W Busse; Dianne Jackowski; Victor M Montori; Holger Schünemann; Sheila Sprague; Derek Mears; Emil H Schemitsch; Dianne Heels-Ansdell; P J Devereaux
Journal:  CMAJ       Date:  2004-02-17       Impact factor: 8.262

Review 8.  Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.

Authors:  Stephan Heres; John Davis; Katja Maino; Elisabeth Jetzinger; Werner Kissling; Stefan Leucht
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

9.  Clinical trial registration: transparency is the watchword.

Authors:  Ida Sim; An-Wen Chan; A Metin Gülmezoglu; Tim Evans; Tikki Pang
Journal:  Lancet       Date:  2006-05-20       Impact factor: 79.321

10.  Study of information submitted by drug companies to licensing authorities.

Authors:  E Hemminki
Journal:  Br Med J       Date:  1980-03-22
View more
  12 in total

1.  Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO.

Authors:  Kay Dickersin; Iain Chalmers
Journal:  J R Soc Med       Date:  2011-12       Impact factor: 5.344

2.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

Review 3.  A lesson learnt: the rise and fall of Lariam and Halfan.

Authors:  Ashley M Croft
Journal:  J R Soc Med       Date:  2007-04       Impact factor: 5.344

4.  Transparency in health technology assessments.

Authors:  Alan Maynard
Journal:  BMJ       Date:  2007-03-24

5.  Managing allegations of research misconduct.

Authors:  Edmund Hey
Journal:  J R Soc Med       Date:  2009-04       Impact factor: 5.344

6.  Reasons for optimism not disillusionment.

Authors:  Ronald L Krall; Frank Rockhold
Journal:  J R Soc Med       Date:  2006-09       Impact factor: 18.000

7.  Public health research systems in the European union.

Authors:  Cláudia Conceição; Mark McCarthy
Journal:  Health Res Policy Syst       Date:  2011-10-04

8.  Modelling of mouse experimental colitis by global property screens: a holistic approach to assess drug effects in inflammatory bowel disease.

Authors:  Johan Gottfries; Silvia Melgar; Erik Michaëlsson
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

9.  Better research for better healthcare.

Authors:  Sophie Petit-Zeman
Journal:  J R Soc Med       Date:  2006-07       Impact factor: 18.000

10.  Is Mandatory Prospective Trial Registration Working to Prevent Publication of Unregistered Trials and Selective Outcome Reporting? An Observational Study of Five Psychiatry Journals That Mandate Prospective Clinical Trial Registration.

Authors:  Amelia Scott; Julia J Rucklidge; Roger T Mulder
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.